Examkin

Soru

Zorluk: Çok zorEnd-of-Life and Palliative Care

A 7878-year-old man with end-stage idiopathic pulmonary fibrosis is admitted to an inpatient palliative care unit. He is transitioning to comfort-focused care and has a do-not-resuscitate/do-not-intubate (DNR/DNI) order. He develops severe, distressing dyspnea at rest. Non-pharmacological measures, including optimal upright positioning, a bedside fan directed at his face, and supplemental oxygen, have been maximized but fail to provide relief. His respiratory rate is 36 breaths per minute36 \text{ breaths per minute}, and he is utilizing accessory muscles. The patient appears extremely anxious and frightened by his inability to catch his breath. Arrange the following clinical steps in the most appropriate chronological sequence for the management of this patient's escalating terminal dyspnea, progressing from the initial pharmacological intervention to the management of truly refractory suffering.

  1. 1Administer an intermittent trial of a low-dose intravenous opioid (e.g., morphine) to alter the central perception of breathlessness.
  2. 2Transition to a continuous intravenous opioid infusion, rapidly titrating the basal rate based on the frequency of required as-needed boluses.
  3. 3Introduce an intravenous benzodiazepine (e.g., lorazepam) as an adjuvant therapy to manage the severe panic and anxiety exacerbating the air hunger.
  4. 4Convene an interdisciplinary team and family meeting to formally designate the patient's symptom as refractory to maximal standard therapies.
  5. 5Initiate proportionate palliative sedation with a continuous infusion of an agent like midazolam to deliberately reduce the level of consciousness.

Cevap

The correct sequence is: (1) Intermittent low-dose opioid trial, (2) Continuous opioid infusion with titration, (3) Adjuvant benzodiazepine for anxiety, (4) Interdisciplinary consensus of refractory symptoms, and (5) Proportionate palliative sedation.
The established protocol for managing terminal dyspnea begins with identifying and treating reversible causes, followed by non-pharmacological measures. Pharmacological management strictly begins with an opioid trial to target central respiratory drive. If relief is unsustained, opioids are escalated to a continuous infusion. Adjuvant therapies, such as benzodiazepines, are added sequentially to target secondary components like panic. If the symptom remains intolerable despite maximal therapy, it must be formally declared refractory by the interdisciplinary team. Only then is proportionate palliative sedation ethically indicated to relieve suffering.

Adım Adım Çözüm

1
Initiate first-line pharmacological therapy.
An intermittent trial of a low-dose intravenous opioid is administered.
Opioids are the primary treatment for terminal dyspnea because they decrease the central respiratory drive and the perception of breathlessness.
2
Escalate primary therapy for sustained relief.
A continuous intravenous opioid infusion is initiated and titrated.
When intermittent doses are insufficient, a continuous infusion provides a steady-state level of medication to prevent breakthrough symptoms.
3
Target the prominent affective component of the symptom.
An adjuvant benzodiazepine is introduced.
The patient is extremely anxious and frightened. Benzodiazepines specifically address the panic and anxiety exacerbating the dyspnea, but they should only follow or accompany opioid optimization.
4
Establish the clinical necessity for last-resort interventions.
An interdisciplinary consensus designates the symptom as refractory.
Ethical and clinical guidelines require formal determination that a symptom is refractory before initiating treatments that deliberately remove consciousness.
5
Implement the treatment of last resort.
Proportionate palliative sedation is initiated.
When suffering cannot be alleviated by any other means, sedation is titrated proportionately to provide comfort until death occurs.

Anahtar Kavram

The stepwise management of terminal dyspnea involves optimizing opioids, adding anxiolytics as adjuvants, formally diagnosing refractoriness, and utilizing palliative sedation as a final measure.
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru